Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - Novartis On Track To Remain A Leader In MS - FEB 2018

Americas December 2017 / United States / Industry

Within the multiple sclerosis (MS) drugs arena, Novartis is facing the arrival of generic Gilenya and competition from Celgene's ozanimod, a likely blockbuster drug of the future. Novartis is looking to sustain its leadership in this disease area, and is pursuing paediatric and secondary progressive MS, which represent areas of unmet need. A paediatric indication for Gilenya would extend the drug's lifecycle, meanwhile pipeline products will help to offset revenue losses as Gilenya succumbs to competition.


Industry Trend Analysis - Pharmaceutical Growth To Slow Amid Pricing Challenges - JAN 2018

Asia November 2017 / Japan / Industry

Japan will remain an important market for innovative drugmakers - the large market size, considerable purchasing power and the strength of the regulatory environment all contribute to significant revenue-earning opportunities for pharmaceutical firms. However, an increasingly tough pricing environment and a push towards the consumption of generic medicines, will require drugmakers to review their selling strategies in the world's third largest pharmaceutical market.


Industry Trend Analysis - Record Biosimilar Approval Rates Are Anticipated For 2018 - FEB 2018

Emerging Europe December 2017 / Europe / Industry

2017 witnessed a noticeable spike in biosimilar approvals in both the US and EU. However, in the US, the issue of interchangeability is still to be resolved, which is becoming increasingly important. A lack of interchangeability guidance will dampen the market potential for biosimilars, and although resolution is unlikely in 2018, FDA guidance can be expected. In both the US and the EU, approval for biosimilar pegfilgrastim looks likely in 2018, but there will be a race amongst several companies to be first, including Sandoz.


Industry Trend Analysis - Namibia - Q1 2018 - FEB 2018

Middle East & Africa December 2017 / Namibia / Industry

Namibia's weak domestic manufacturing capabilities and strong colonial ties with South Africa will ensure the country continues to import the majority of its pharmaceutical needs over the coming years. Despite a relatively attractive business environment, multinational drugmakers will continue to use South Africa as the main channel trough which medicines are imported into the country, and will be unlikely to establish a direct manufacturing presence. Local production of antiretroviral medicines will give a small boost to the country's limited export potential.


Industry Trend Analysis - Pharmaceuticals & Healthcare Outlook For 2018: Western Europe - FEB 2018

Western Europe December 2017 / Europe / Industry

Drugmakers in Western Europe will need to continue to assess their business strategies, R&D focus and product portfolios. Despite the growing demand for and consumption of high-value medicines in the region, government focus on the cost-effective prescribing of medicines and the promotion of generic drugs and biosimilars will require companies to seek efficiencies in order to boost revenue streams. It is our view that in addition to employing internal strategies - including the restructuring of business - multinational drugmakers will increasingly participate in discussions regarding industry regulations, drug pricing and sustainable spending.